Press Release- 2013

Nes-Ziona, 21^st Oct, 2013. Vaxil receives approval for a trial using ImMucin in patients with metastatic breast cancer Read More

Nes-Ziona, 12^th June, 2013.Vaxil reports promising results from its VAXIL-002 follow-up clinical trial of ImMucin in multiple myeloma patients Read More

Nes-Ziona, 9^th April, 2013. Vaxil Reports Positive Results From a Phase I/II Clinical Trial Using Its Therapeutic Cancer Vaccine, ImMucin, In Patients With Multiple Myeloma Read More

Nes-Ziona, 23^th January, 2013. Vaxil Bio Ltd. announced a Collaboration with the University of Santiago de Compostela, Spain Read More

Nes-Ziona, 21^st January, 2013. Vaxil Bio Ltd. announced today that it is being moved up to Full Main Board Listing on the Tel Aviv Stock Exchange (TASE) Read More